JP Morgan Maintains Overweight on Relay Therapeutics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $29 to $23.

August 07, 2024 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Eric Joseph maintains an Overweight rating on Relay Therapeutics but lowers the price target from $29 to $23.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100